Phaseline

Companies › Beijing Konruns Pharmaceutical

Beijing Konruns Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KC1036
unclear - not stated
–Phase 3Esophageal Squamous Cell Carcinoma; Ewing Sarcoma; Esophageal Squamous Cell Carcinoma (ESCC)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06194734KC1036Phase 3Esophageal Squamous Cell CarcinomaOncologyDec 2026
NCT06564272KC1036Phase 2Ewing SarcomaOncologyApr 2027
NCT07481058KC1036Phase 2Esophageal Squamous Cell Carcinoma (ESCC)OncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma ABX advanced biochemical compounds

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.